British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic

Nicholas A Kennedy; Gareth-Rhys Jones; Christopher A Lamb; Richard Appleby; Ian Arnott; R Mark Beattie; Stuart Bloom; Alenka J Brooks; Rachel Cooney; Robin J Dart; Cathryn Edwards; Aileen Fraser; Daniel R Gaya; Subrata Ghosh; Kay Greveson; Richard Hansen; Ailsa Hart; A Barney Hawthorne; Bu'Hussain Hayee; Jimmy K Limdi; Charles D Murray; Gareth C Parkes; Miles Parkes; Kamal Patel; Richard C Pollok; Nick Powell; Chris S Probert; Tim Raine; Shaji Sebastian; Christian Selinger; Philip J Smith; Catherine Stansfield; Lisa Younge; James O Lindsay; Peter M Irving; Charlie W Lees

doi:10.1136/gutjnl-2020-321244

British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic

Nicholas A Kennedy, Gareth-Rhys Jones, Christopher A Lamb, Richard Appleby, Ian Arnott, R Mark Beattie, Stuart Bloom, Alenka J Brooks, Rachel Cooney, Robin J Dart, Cathryn Edwards, Aileen Fraser, Daniel R Gaya, Subrata Ghosh, Kay Greveson, Richard Hansen, Ailsa Hart, A Barney Hawthorne, Bu'Hussain Hayee, Jimmy K LimdiCharles D Murray, Gareth C Parkes, Miles Parkes, Kamal Patel, Richard C Pollok, Nick Powell, Chris S Probert, Tim Raine, Shaji Sebastian, Christian Selinger, Philip J Smith, Catherine Stansfield, Lisa Younge, James O Lindsay, Peter M Irving, Charlie W Lees

Research output: Contribution to journal › Article › peer-review

105 Citations (Scopus)

169 Downloads (Pure)

Abstract

The COVID-19 pandemic is putting unprecedented pressures on healthcare systems globally. Early insights have been made possible by rapid sharing of data from China and Italy. In the UK, we have rapidly mobilised inflammatory bowel disease (IBD) centres in order that preparations can be made to protect our patients and the clinical services they rely on. This is a novel coronavirus; much is unknown as to how it will affect people with IBD. We also lack information about the impact of different immunosuppressive medications. To address this uncertainty, the British Society of Gastroenterology (BSG) COVID-19 IBD Working Group has used the best available data and expert opinion to generate a risk grid that groups patients into highest, moderate and lowest risk categories. This grid allows patients to be instructed to follow the UK government's advice for shielding, stringent and standard advice regarding social distancing, respectively. Further considerations are given to service provision, medical and surgical therapy, endoscopy, imaging and clinical trials.

Original language	English
Pages (from-to)	984-990
Number of pages	7
Journal	Gut
Volume	69
Issue number	6
Early online date	17 Apr 2020
DOIs	https://doi.org/10.1136/gutjnl-2020-321244
Publication status	Published - Jun 2020

Bibliographical note

Keywords

Antiviral Agents/adverse effects
Betacoronavirus
Coronavirus Infections/complications
Humans
Immunosuppressive Agents/adverse effects
Inflammatory Bowel Diseases/therapy
Pandemics
Pneumonia, Viral/complications
Risk Assessment
United Kingdom
crohn's colitis
ulcerative colitis
crohn's disease

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.1136/gutjnl-2020-321244Licence: Creative Commons: Attribution-NonCommercial (CC BY-NC)

Kennedy_et_al_British_Society_of_Gastroenterology_guidance_for_management_of_inflammatory_bowel_disease_during_the_COVID-19_pandemic_Gut_2020Final published version, 1.34 MBLicence: Creative Commons: Attribution-NonCommercial (CC BY-NC)

http://dx.doi.org/10.1136/gutjnl-2020-321244Licence: Creative Commons: Attribution-NonCommercial (CC BY-NC)

Cite this

Kennedy, N. A., Jones, G-R., Lamb, C. A., Appleby, R., Arnott, I., Beattie, R. M., Bloom, S., Brooks, A. J., Cooney, R., Dart, R. J., Edwards, C., Fraser, A., Gaya, D. R., Ghosh, S., Greveson, K., Hansen, R., Hart, A., Hawthorne, A. B., Hayee, BH., ... Lees, C. W. (2020). British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut, 69(6), 984-990. Advance online publication. https://doi.org/10.1136/gutjnl-2020-321244

@article{daa0d9eef7344cefb0171adcd1650a3e,

title = "British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic",

abstract = "The COVID-19 pandemic is putting unprecedented pressures on healthcare systems globally. Early insights have been made possible by rapid sharing of data from China and Italy. In the UK, we have rapidly mobilised inflammatory bowel disease (IBD) centres in order that preparations can be made to protect our patients and the clinical services they rely on. This is a novel coronavirus; much is unknown as to how it will affect people with IBD. We also lack information about the impact of different immunosuppressive medications. To address this uncertainty, the British Society of Gastroenterology (BSG) COVID-19 IBD Working Group has used the best available data and expert opinion to generate a risk grid that groups patients into highest, moderate and lowest risk categories. This grid allows patients to be instructed to follow the UK government's advice for shielding, stringent and standard advice regarding social distancing, respectively. Further considerations are given to service provision, medical and surgical therapy, endoscopy, imaging and clinical trials.",

keywords = "Antiviral Agents/adverse effects, Betacoronavirus, Coronavirus Infections/complications, Humans, Immunosuppressive Agents/adverse effects, Inflammatory Bowel Diseases/therapy, Pandemics, Pneumonia, Viral/complications, Risk Assessment, United Kingdom, crohn's colitis, ulcerative colitis, crohn's disease",

author = "Kennedy, {Nicholas A} and Gareth-Rhys Jones and Lamb, {Christopher A} and Richard Appleby and Ian Arnott and Beattie, {R Mark} and Stuart Bloom and Brooks, {Alenka J} and Rachel Cooney and Dart, {Robin J} and Cathryn Edwards and Aileen Fraser and Gaya, {Daniel R} and Subrata Ghosh and Kay Greveson and Richard Hansen and Ailsa Hart and Hawthorne, {A Barney} and Bu'Hussain Hayee and Limdi, {Jimmy K} and Murray, {Charles D} and Parkes, {Gareth C} and Miles Parkes and Kamal Patel and Pollok, {Richard C} and Nick Powell and Probert, {Chris S} and Tim Raine and Shaji Sebastian and Christian Selinger and Smith, {Philip J} and Catherine Stansfield and Lisa Younge and Lindsay, {James O} and Irving, {Peter M} and Lees, {Charlie W}",

note = "{\textcopyright} Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.",

year = "2020",

month = jun,

doi = "10.1136/gutjnl-2020-321244",

language = "English",

volume = "69",

pages = "984--990",

journal = "Gut",

issn = "0017-5749",

publisher = "BMJ Publishing Group",

number = "6",

}

Kennedy, NA, Jones, G-R, Lamb, CA, Appleby, R, Arnott, I, Beattie, RM, Bloom, S, Brooks, AJ, Cooney, R, Dart, RJ, Edwards, C, Fraser, A, Gaya, DR, Ghosh, S, Greveson, K, Hansen, R, Hart, A, Hawthorne, AB, Hayee, BH, Limdi, JK, Murray, CD, Parkes, GC, Parkes, M, Patel, K, Pollok, RC, Powell, N, Probert, CS, Raine, T, Sebastian, S, Selinger, C, Smith, PJ, Stansfield, C, Younge, L, Lindsay, JO, Irving, PM & Lees, CW 2020, 'British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic', Gut, vol. 69, no. 6, pp. 984-990. https://doi.org/10.1136/gutjnl-2020-321244

TY - JOUR

T1 - British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic

AU - Kennedy, Nicholas A

AU - Jones, Gareth-Rhys

AU - Lamb, Christopher A

AU - Appleby, Richard

AU - Arnott, Ian

AU - Beattie, R Mark

AU - Bloom, Stuart

AU - Brooks, Alenka J

AU - Cooney, Rachel

AU - Dart, Robin J

AU - Edwards, Cathryn

AU - Fraser, Aileen

AU - Gaya, Daniel R

AU - Ghosh, Subrata

AU - Greveson, Kay

AU - Hansen, Richard

AU - Hart, Ailsa

AU - Hawthorne, A Barney

AU - Hayee, Bu'Hussain

AU - Limdi, Jimmy K

AU - Murray, Charles D

AU - Parkes, Gareth C

AU - Parkes, Miles

AU - Patel, Kamal

AU - Pollok, Richard C

AU - Powell, Nick

AU - Probert, Chris S

AU - Raine, Tim

AU - Sebastian, Shaji

AU - Selinger, Christian

AU - Smith, Philip J

AU - Stansfield, Catherine

AU - Younge, Lisa

AU - Lindsay, James O

AU - Irving, Peter M

AU - Lees, Charlie W

PY - 2020/6

Y1 - 2020/6

N2 - The COVID-19 pandemic is putting unprecedented pressures on healthcare systems globally. Early insights have been made possible by rapid sharing of data from China and Italy. In the UK, we have rapidly mobilised inflammatory bowel disease (IBD) centres in order that preparations can be made to protect our patients and the clinical services they rely on. This is a novel coronavirus; much is unknown as to how it will affect people with IBD. We also lack information about the impact of different immunosuppressive medications. To address this uncertainty, the British Society of Gastroenterology (BSG) COVID-19 IBD Working Group has used the best available data and expert opinion to generate a risk grid that groups patients into highest, moderate and lowest risk categories. This grid allows patients to be instructed to follow the UK government's advice for shielding, stringent and standard advice regarding social distancing, respectively. Further considerations are given to service provision, medical and surgical therapy, endoscopy, imaging and clinical trials.

AB - The COVID-19 pandemic is putting unprecedented pressures on healthcare systems globally. Early insights have been made possible by rapid sharing of data from China and Italy. In the UK, we have rapidly mobilised inflammatory bowel disease (IBD) centres in order that preparations can be made to protect our patients and the clinical services they rely on. This is a novel coronavirus; much is unknown as to how it will affect people with IBD. We also lack information about the impact of different immunosuppressive medications. To address this uncertainty, the British Society of Gastroenterology (BSG) COVID-19 IBD Working Group has used the best available data and expert opinion to generate a risk grid that groups patients into highest, moderate and lowest risk categories. This grid allows patients to be instructed to follow the UK government's advice for shielding, stringent and standard advice regarding social distancing, respectively. Further considerations are given to service provision, medical and surgical therapy, endoscopy, imaging and clinical trials.

KW - Antiviral Agents/adverse effects

KW - Betacoronavirus

KW - Coronavirus Infections/complications

KW - Humans

KW - Immunosuppressive Agents/adverse effects

KW - Inflammatory Bowel Diseases/therapy

KW - Pandemics

KW - Pneumonia, Viral/complications

KW - Risk Assessment

KW - United Kingdom

KW - crohn's colitis

KW - ulcerative colitis

KW - crohn's disease

UR - http://www.scopus.com/inward/record.url?scp=85083729236&partnerID=8YFLogxK

U2 - 10.1136/gutjnl-2020-321244

DO - 10.1136/gutjnl-2020-321244

M3 - Article

C2 - 32303607

SN - 0017-5749

VL - 69

SP - 984

EP - 990

JO - Gut

JF - Gut

IS - 6

ER -

British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this